|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review显示文摘AIM:To review literature on efficacy and safety of octreotide-long-acting repeatable(LAR)used at doses higher than the Food and Drug Administration(FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors(NETs).METHODS:We searched Pub Med and Cochrane Library from 1998-2012,5 conferences(American Society of Clinical Oncology,Endocrine Society,European Neuroendocrine Tumor Society,European Society for Medical Oncology,North American Neuroendocrine Tumor Society)from 2000-2013 using Me SH and keyterms including neuroendocrine tumors,carcinoid tumor,carcinoma,neuroendocrine,and octreotide.Bibliographies of accepted articles were also searched.Two reviewers reviewed titles,abstracts,and full-length articles.Studies that reported data on efficacy and safety of≥30 mg/mo octreotide-LAR for NETs in human subjects,published in any language were included in the review.RESULTS:The search identified 1086 publications,of which 238 underwent full-text review(20 were translated into English);17 were included in the review.Studies varied in designs,subjects,octreotide-LAR regimens,and definition of outcomes.Eleven studies reported use of higher doses to control symptoms and tumor progression,although symptom severity and formal quality-of-life analysis were not quantitatively measured.Ten studies reported efficacy,describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo.Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression.Eight studies reported safety;there was no evidence of increased toxicity associated with doses of octreotide-LAR>30 mg/mo.CONCLUSION:As reported in this review,octreotide-LAR at doses>30 mg/mo is being prescribed for symptom and tumor control in NET patients.Furthermore,expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms. | Michael S Broder David Beenhouwer Jonathan R Strosberg Maureen P Neary Dasha Cherepanov | 2015 | World Journal of Gastroenterology2015，21，6： | 8 |
| 2 | Cellular mechanisms of mainstream cigarette smoke-induced lung epithelial tight junction permeability changes in vitro 显示文摘 | Olivera DS Boggs SE Beenhouwer C | 2007 | Inhalation Toxicology2007，19，1： | 1 |
| 3 | Cellular mechanisms of mainstream cigarette smoke-induced lung epithelial tight junction permeability changes in vitro显示文摘 | Olivera DS Boggs SE Beenhouwer C | | 0，，： | 1 |
| 4 | High affinitymimotope of the polysaccharide capsule of Cryptococcusneoformans identified from an evolutionary phage peptidelibrary显示文摘 | Beenhouwer DO May RJ Philippe V Scharff MD | 2002 | J Immunol2002，169，12： | 1 |
| 5 | Detection of rifampin resistance in sputum biopsy specimens from tuberculosis patients by PCR and line probe assay显示文摘 | De Beenhouwer H Jannes G | 1995 | Tuber lung Dis1995，4，3： | 1 |
| 6 | How relevant were the models used to measure the impact of Panton- Valentine leukocidin in human staphylococcal infections? 显示文摘 | Schwartzman WA Beenhouwer DO Schaberg DR | 2007 | J Infect Dis2007，195，11： | 1 |
| 7 | Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay 显示文摘 | De Beenhouwer H Lhiang Z Jannes G | 1995 | Tuber Lung Dis1995，76，42： | 1 |
| 8 | Cellular mechanisms of mainstream cigarette smoke-induced lung epithelial tight junction permeability changes in vitro 显示文摘 | Olivera D S Boggs S E Beenhouwer C | 2007 | Inhal Toxicol2007，19，1： | 1 |
| 9 | High affinity mimotope of the polysaccharide capsule of Cryptococcus Neoformans identified from an evolutionary phage peptide library显示文摘 | Beenhouwer DO May RJ Valadon P | 2002 | J Immunol2002，169，： | 1 |
| 10 | CLASSIC PROTEOMICS:THE USE OF IMMUNOFLUORESCENCE MICROSCOPY TO STUDY THE EFFECT OF CIGARETIE SMOKE ON HUMAN LUNG EPTTHELIUM显示文摘 | Olivera D Beenhouwer C Herrera L | | 0，，： | 1 |
| 11 | Cluster computing software for GATE simulations 显示文摘 | De Beenhouwer J Staelens S Kruecker D | 2007 | Med Phys2007，34，： | 1 |
| 12 | Detection and identification of mycobacteria by DNA amplification and oligonucleotide-specific capture plate hybridization显示文摘 | Beenhouwer HD Zhong L Rijk PD | 1995 | J Clin Microbiol1995，33，： | 1 |
| 13 | Antibodies to keyhole limpet hemocyanin cross react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates:implications for vaccine development显示文摘 | MAY R J BEENHOUWER D O SCHRAFF M D | 2003 | J Immunol2003，171，9： | 1 |
| 14 | Human immu- noglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection 显示文摘 | Beenhouwer DO Yoo EM Lai CW | 2007 | Infect Immun2007，75，： | 1 |
| 15 | Cellular mechanisms of mainstream cigarette smoke-induced lung epithelial tight junction permeability changes in vitro显示文摘 | Olivera D S Boggs S E Beenhouwer C | 2007 | Inhal Toxicol2007，19，1： | 1 |
| 16 | Identification of Mycobacterium species by using amplified ribosomal DNA restriction analysis显示文摘 | Vaneechoutte M De Beenhouwer H Claeys G | 1993 | J Clin Microbiol1993，31，8： | 1 |
| 17 | High affinity mimotope of the polysaccharide capsule of cryptococcus neoformans identified from an evolutionary phage peptide library显示文摘 | Beenhouwer D O May R J Valadon P | 2002 | J Immunol2002，169，12： | 1 |
| 18 | Both forest fragmentation and coffee cultivation negatively affect epiphytic orchid diversity in Ethiopian moist evergreen Afromontane forests 显示文摘 | HUNDERA K AERTS R BEENHOUWER MD 2013 | 2013 | Biol Conserv2013，159，5： | 1 |
| 19 | Rapid Detection of rifampicin resistance in sputum and bilpsy specimens from tuberculosis patients by PCR and line probe assay显示文摘 | De Beenhouwer H Lhiang Z Jannes G | 1995 | Tuber Lung Dis1995，76，5： | 1 |
| 20 | Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates:implications for vaccine development显示文摘 | May RJ Beenhouwer DO Scharff MD | 2003 | J Immunol2003，171，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员